Artivion (NYSE:AORT) Announces Earnings Results, Beats Expectations By $0.04 EPS

Artivion (NYSE:AORT) posted its earnings results on Monday. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.04, Yahoo Finance reports. Artivion had a positive return on equity of 3.02% and a negative net margin of 8.67%. The business had revenue of $97.43 million during the quarter, compared to analysts’ expectations of $92.30 million. During the same period in the prior year, the business earned $0.02 EPS. Artivion updated its FY 2024 guidance to EPS.

Artivion Price Performance

Shares of AORT opened at $23.85 on Wednesday. The stock has a market capitalization of $982.62 million, a P/E ratio of -31.80 and a beta of 1.66. Artivion has a twelve month low of $12.16 and a twelve month high of $25.51. The company has a 50 day moving average of $20.48 and a 200-day moving average of $18.14. The company has a quick ratio of 3.43, a current ratio of 4.85 and a debt-to-equity ratio of 1.10.

Insider Transactions at Artivion

In other news, CAO Amy Horton sold 1,695 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $18.86, for a total transaction of $31,967.70. Following the completion of the transaction, the chief accounting officer now directly owns 122,345 shares of the company’s stock, valued at approximately $2,307,426.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, VP Andrew M. Green sold 1,462 shares of the stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $20.00, for a total value of $29,240.00. Following the completion of the sale, the vice president now owns 41,121 shares of the company’s stock, valued at approximately $822,420. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Amy Horton sold 1,695 shares of the stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $18.86, for a total value of $31,967.70. Following the completion of the sale, the chief accounting officer now directly owns 122,345 shares of the company’s stock, valued at approximately $2,307,426.70. The disclosure for this sale can be found here. Insiders sold 149,952 shares of company stock valued at $2,891,627 in the last ninety days. 8.10% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Needham & Company LLC increased their target price on Artivion from $25.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday. Stifel Nicolaus increased their target price on Artivion from $22.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.